In NSCLC, HER2 overexpression is typically not driven by HER2 amplification but rather by polysomy, in contrast to breast cancer where HER2 amplification is strongly correlated with HER2 expression. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.